Recombinant Antibodies

Galcanezumab (anti-CALCA) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab (anti-CALCA) can be used for migraine or cluster headaches research.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Gantenerumab (anti-Amyloid Beta) is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab (anti-Amyloid Beta) can be used for Alzheimer's disease research.Purity&gt95%

Gantenerumab (anti-Amyloid Beta) is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab (anti-Amyloid Beta) can be used for Alzheimer's disease research.Purity&gt95%

Gantenerumab (anti-Amyloid Beta) is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab (anti-Amyloid Beta) can be used for Alzheimer's disease research.Purity&gt95%

Gantenerumab (anti-Amyloid Beta) is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab (anti-Amyloid Beta) can be used for Alzheimer's disease research.Purity&gt95%

Gevokizumab (anti-IL-1b) is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab (anti-IL-1b) selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI)

Gevokizumab (anti-IL-1b) is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab (anti-IL-1b) selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI)

Gevokizumab (anti-IL-1b) is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab (anti-IL-1b) selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI)

Gevokizumab (anti-IL-1b) is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab (anti-IL-1b) selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI)

Girentuximab (anti-CA9) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt

Girentuximab (anti-CA9) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt

Girentuximab (anti-CA9) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt